Cargando…

Non-Pharmacological Therapeutic Options for Liver Metastases in Advanced Neuroendocrine Tumors

The incidence of liver metastasis in digestive neuroendocrine tumors is high. Their presence appears as an important prognostic factor in terms of quality of life and survival. These tumors may be symptomatic because of the tumor burden itself and/or the hormonal hyper-secretion induced by the tumor...

Descripción completa

Detalles Bibliográficos
Autores principales: Dermine, Solène, Palmieri, Lola-Jade, Lavolé, Julie, Barré, Amélie, Dohan, Antony, Abou Ali, Einas, Cottereau, Anne-Ségolène, Gaujoux, Sébastien, Brezault, Catherine, Chaussade, Stanislas, Coriat, Romain
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6912565/
https://www.ncbi.nlm.nih.gov/pubmed/31703375
http://dx.doi.org/10.3390/jcm8111907
_version_ 1783479486702944256
author Dermine, Solène
Palmieri, Lola-Jade
Lavolé, Julie
Barré, Amélie
Dohan, Antony
Abou Ali, Einas
Cottereau, Anne-Ségolène
Gaujoux, Sébastien
Brezault, Catherine
Chaussade, Stanislas
Coriat, Romain
author_facet Dermine, Solène
Palmieri, Lola-Jade
Lavolé, Julie
Barré, Amélie
Dohan, Antony
Abou Ali, Einas
Cottereau, Anne-Ségolène
Gaujoux, Sébastien
Brezault, Catherine
Chaussade, Stanislas
Coriat, Romain
author_sort Dermine, Solène
collection PubMed
description The incidence of liver metastasis in digestive neuroendocrine tumors is high. Their presence appears as an important prognostic factor in terms of quality of life and survival. These tumors may be symptomatic because of the tumor burden itself and/or the hormonal hyper-secretion induced by the tumor. Surgery is the treatment of choice for resectable tumors and metastasis. Nevertheless, surgery is only possible in a small number of cases. The management of non-resectable liver metastasis is a challenge. The literature is rich but consists predominantly in small retrospective series with a low level of proof. Thus, the choice of one technique over another could be difficult. Local ablative techniques (radiofrequency) or trans-catheter intra-arterial liver-directed treatments (hepatic artery embolization, chemo-embolization, and radio-embolization) are frequently considered for liver metastasis. In the present review, we focus on these different therapeutic approaches in advanced neuroendocrine tumors, results (clinical and radiological), and overall efficacy, and summarize recommendations to help physicians in their clinical practice.
format Online
Article
Text
id pubmed-6912565
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-69125652020-01-02 Non-Pharmacological Therapeutic Options for Liver Metastases in Advanced Neuroendocrine Tumors Dermine, Solène Palmieri, Lola-Jade Lavolé, Julie Barré, Amélie Dohan, Antony Abou Ali, Einas Cottereau, Anne-Ségolène Gaujoux, Sébastien Brezault, Catherine Chaussade, Stanislas Coriat, Romain J Clin Med Review The incidence of liver metastasis in digestive neuroendocrine tumors is high. Their presence appears as an important prognostic factor in terms of quality of life and survival. These tumors may be symptomatic because of the tumor burden itself and/or the hormonal hyper-secretion induced by the tumor. Surgery is the treatment of choice for resectable tumors and metastasis. Nevertheless, surgery is only possible in a small number of cases. The management of non-resectable liver metastasis is a challenge. The literature is rich but consists predominantly in small retrospective series with a low level of proof. Thus, the choice of one technique over another could be difficult. Local ablative techniques (radiofrequency) or trans-catheter intra-arterial liver-directed treatments (hepatic artery embolization, chemo-embolization, and radio-embolization) are frequently considered for liver metastasis. In the present review, we focus on these different therapeutic approaches in advanced neuroendocrine tumors, results (clinical and radiological), and overall efficacy, and summarize recommendations to help physicians in their clinical practice. MDPI 2019-11-07 /pmc/articles/PMC6912565/ /pubmed/31703375 http://dx.doi.org/10.3390/jcm8111907 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Dermine, Solène
Palmieri, Lola-Jade
Lavolé, Julie
Barré, Amélie
Dohan, Antony
Abou Ali, Einas
Cottereau, Anne-Ségolène
Gaujoux, Sébastien
Brezault, Catherine
Chaussade, Stanislas
Coriat, Romain
Non-Pharmacological Therapeutic Options for Liver Metastases in Advanced Neuroendocrine Tumors
title Non-Pharmacological Therapeutic Options for Liver Metastases in Advanced Neuroendocrine Tumors
title_full Non-Pharmacological Therapeutic Options for Liver Metastases in Advanced Neuroendocrine Tumors
title_fullStr Non-Pharmacological Therapeutic Options for Liver Metastases in Advanced Neuroendocrine Tumors
title_full_unstemmed Non-Pharmacological Therapeutic Options for Liver Metastases in Advanced Neuroendocrine Tumors
title_short Non-Pharmacological Therapeutic Options for Liver Metastases in Advanced Neuroendocrine Tumors
title_sort non-pharmacological therapeutic options for liver metastases in advanced neuroendocrine tumors
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6912565/
https://www.ncbi.nlm.nih.gov/pubmed/31703375
http://dx.doi.org/10.3390/jcm8111907
work_keys_str_mv AT derminesolene nonpharmacologicaltherapeuticoptionsforlivermetastasesinadvancedneuroendocrinetumors
AT palmierilolajade nonpharmacologicaltherapeuticoptionsforlivermetastasesinadvancedneuroendocrinetumors
AT lavolejulie nonpharmacologicaltherapeuticoptionsforlivermetastasesinadvancedneuroendocrinetumors
AT barreamelie nonpharmacologicaltherapeuticoptionsforlivermetastasesinadvancedneuroendocrinetumors
AT dohanantony nonpharmacologicaltherapeuticoptionsforlivermetastasesinadvancedneuroendocrinetumors
AT aboualieinas nonpharmacologicaltherapeuticoptionsforlivermetastasesinadvancedneuroendocrinetumors
AT cottereauannesegolene nonpharmacologicaltherapeuticoptionsforlivermetastasesinadvancedneuroendocrinetumors
AT gaujouxsebastien nonpharmacologicaltherapeuticoptionsforlivermetastasesinadvancedneuroendocrinetumors
AT brezaultcatherine nonpharmacologicaltherapeuticoptionsforlivermetastasesinadvancedneuroendocrinetumors
AT chaussadestanislas nonpharmacologicaltherapeuticoptionsforlivermetastasesinadvancedneuroendocrinetumors
AT coriatromain nonpharmacologicaltherapeuticoptionsforlivermetastasesinadvancedneuroendocrinetumors